Ligand Pharmaceuticals reported U$21.043 million in Pre-Tax Profit for its second fiscal quarter of 2020.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Pre Tax Profit Change
Acceleron Pharma U$ -19M 32M
Agenus U$ -48.244M 2.973M
Amgen U$ 2918M 77M
Anika Therapeutics U$ -6.813M 12.084M
Baxter International U$ 394M 103M
Bristol Myers Squibb U$ 4357M 361M
Clovis Oncology U$ -100M 2M
Dicerna Pharmaceuticals U$ -23M 17M
Eli Lilly And U$ 1988.3M 137.6M
Enanta Pharmaceuticals U$ -22M 12M
Gilead Sciences U$ 1804M 845M
GlaxoSmithKline 1541M 956M
Glaxosmithkline U$ 3200.863M 1288.284M
Harsco U$ 15M 1M
Immunogen U$ -24.298M 4.79M
Insmed -6142600 490200
Ligand Pharmaceuticals U$ 21.043M 1.755M
Merk U$ 4096M 510M
Pacira Pharmaceuticals U$ 4.977M 18.251M
Pfizer U$ 5152M 170M
Teva Pharmaceutical Industries U$ 643M 106M
Veracyte U$ -11.025M 0.691M